Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Vyxeos + Gilteritinib for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Tampa, Florida
This trial combines Vyxeos, a chemotherapy drug, and Gilteritinib, a targeted therapy, for patients with a specific type of acute myeloid leukemia. Vyxeos attacks cancer cells using a combination of drugs, while Gilteritinib blocks a protein that helps these cancer cells grow. The goal is to see if this combination can help patients who have not responded to other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service